Last reviewed · How we verify

NCT05426629

Hydraderm for Androgenic Alopecia

Withdrawn Phase 4 Last updated 27 January 2025
What this trial tests

Phase 4 trial testing Venus Glow in Androgenic Alopecia. Withdrawn.

Timeline
14 March 2022
Primary endpoint
21 April 2025
21 April 2025

Quick facts

Lead sponsorUniversity of Minnesota
PhasePhase 4
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Start date14 March 2022
Primary completion21 April 2025
Estimated completion21 April 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Minnesota

Who can join

Adults 18 to 65, any sex, with Androgenic Alopecia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study will be focused on evaluating the use of hydradermabrasion on the scalp. The study aims to assess the effect of this treatment on scalp health and hair growth.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Venus Glow

Trials testing the same drug.

Other recruiting trials for Androgenic Alopecia

Currently open trials in the same condition.

Other University of Minnesota trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05426629.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing